Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Modulation of blood pressure by central melanocortinergic pathways.
Greenfield JR, Miller JW, Keogh JM, Henning E, Satterwhite JH, Cameron GS, Astruc B, Mayer JP, Brage S, See TC, Lomas DJ, O'Rahilly S, Farooqi IS. Greenfield JR, et al. Among authors: cameron gs. N Engl J Med. 2009 Jan 1;360(1):44-52. doi: 10.1056/NEJMoa0803085. Epub 2008 Dec 17. N Engl J Med. 2009. PMID: 19092146 Free article.
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL; UNCOVER-1 Study Group; UNCOVER-2 Study Group; UNCOVER-3 Study Group. Gordon KB, et al. Among authors: cameron gs. N Engl J Med. 2016 Jul 28;375(4):345-56. doi: 10.1056/NEJMoa1512711. Epub 2016 Jun 8. N Engl J Med. 2016. PMID: 27299809 Free article. Clinical Trial.
A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab.
Edson-Heredia E, Banerjee S, Zhu B, Maeda-Chubachi T, Cameron GS, Shen W, Heffernan MP, Gordon KB, Leonardi CL. Edson-Heredia E, et al. Among authors: cameron gs. J Eur Acad Dermatol Venereol. 2016 May;30(5):864-5. doi: 10.1111/jdv.13032. Epub 2015 Mar 13. J Eur Acad Dermatol Venereol. 2016. PMID: 25773781 Clinical Trial. No abstract available.
A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors.
Genovese MC, Greenwald M, Cho CS, Berman A, Jin L, Cameron GS, Benichou O, Xie L, Braun D, Berclaz PY, Banerjee S. Genovese MC, et al. Among authors: cameron gs. Arthritis Rheumatol. 2014 Jul;66(7):1693-704. doi: 10.1002/art.38617. Arthritis Rheumatol. 2014. PMID: 24623718 Clinical Trial.
60 results